CN116671631A - 储氢牡蛎钙在防治ⅱ型糖尿病的特殊医学用途食品、保健品及药品中的应用 - Google Patents
储氢牡蛎钙在防治ⅱ型糖尿病的特殊医学用途食品、保健品及药品中的应用 Download PDFInfo
- Publication number
- CN116671631A CN116671631A CN202310662633.8A CN202310662633A CN116671631A CN 116671631 A CN116671631 A CN 116671631A CN 202310662633 A CN202310662633 A CN 202310662633A CN 116671631 A CN116671631 A CN 116671631A
- Authority
- CN
- China
- Prior art keywords
- hop
- hydrogen
- treatment
- calcium
- oyster
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title claims abstract description 58
- 241000237502 Ostreidae Species 0.000 title claims abstract description 58
- 229910052791 calcium Inorganic materials 0.000 title claims abstract description 58
- 239000011575 calcium Substances 0.000 title claims abstract description 58
- 235000020636 oyster Nutrition 0.000 title claims abstract description 58
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title claims abstract description 22
- 239000003814 drug Substances 0.000 title claims abstract description 9
- 235000013305 food Nutrition 0.000 title claims abstract description 7
- 230000036541 health Effects 0.000 title claims abstract description 7
- 229910052739 hydrogen Inorganic materials 0.000 title claims description 71
- 239000001257 hydrogen Substances 0.000 title claims description 71
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 title claims description 69
- 238000003860 storage Methods 0.000 title claims description 37
- 229940079593 drug Drugs 0.000 claims abstract description 5
- 238000011282 treatment Methods 0.000 claims description 103
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 38
- 239000008103 glucose Substances 0.000 claims description 38
- 210000005228 liver tissue Anatomy 0.000 claims description 29
- 210000003205 muscle Anatomy 0.000 claims description 24
- 230000014509 gene expression Effects 0.000 claims description 21
- 210000002966 serum Anatomy 0.000 claims description 20
- 150000002632 lipids Chemical class 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 210000003486 adipose tissue brown Anatomy 0.000 claims description 11
- 230000015572 biosynthetic process Effects 0.000 claims description 11
- 210000005084 renal tissue Anatomy 0.000 claims description 11
- 238000003786 synthesis reaction Methods 0.000 claims description 11
- 210000004185 liver Anatomy 0.000 claims description 10
- 210000000028 corpus adiposum pararenale Anatomy 0.000 claims description 9
- 201000010063 epididymitis Diseases 0.000 claims description 9
- 230000002757 inflammatory effect Effects 0.000 claims description 9
- 230000037356 lipid metabolism Effects 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 241000548230 Crassostrea angulata Species 0.000 claims description 2
- 230000036765 blood level Effects 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 241000237501 Crassostrea Species 0.000 claims 2
- 241000699670 Mus sp. Species 0.000 description 71
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 33
- 210000004369 blood Anatomy 0.000 description 32
- 239000008280 blood Substances 0.000 description 32
- 108090000623 proteins and genes Proteins 0.000 description 27
- 102000004169 proteins and genes Human genes 0.000 description 24
- 239000003642 reactive oxygen metabolite Substances 0.000 description 18
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 16
- 239000007864 aqueous solution Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 15
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 14
- 230000002438 mitochondrial effect Effects 0.000 description 14
- 230000002265 prevention Effects 0.000 description 14
- 210000005013 brain tissue Anatomy 0.000 description 13
- 238000001514 detection method Methods 0.000 description 13
- 239000000243 solution Substances 0.000 description 11
- 238000001262 western blot Methods 0.000 description 10
- 235000021588 free fatty acids Nutrition 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 235000012000 cholesterol Nutrition 0.000 description 8
- 210000005003 heart tissue Anatomy 0.000 description 8
- 230000002503 metabolic effect Effects 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 210000003462 vein Anatomy 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 7
- 108090001061 Insulin Proteins 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 229940125396 insulin Drugs 0.000 description 7
- 238000012544 monitoring process Methods 0.000 description 7
- 238000011321 prophylaxis Methods 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 208000004930 Fatty Liver Diseases 0.000 description 6
- 206010019708 Hepatic steatosis Diseases 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 208000010706 fatty liver disease Diseases 0.000 description 6
- 210000003470 mitochondria Anatomy 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 231100000240 steatosis hepatitis Toxicity 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000004898 mitochondrial function Effects 0.000 description 5
- 230000036542 oxidative stress Effects 0.000 description 5
- 239000008055 phosphate buffer solution Substances 0.000 description 5
- 238000007789 sealing Methods 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 229930040373 Paraformaldehyde Natural products 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 238000010241 blood sampling Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000004043 dyeing Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229920002866 paraformaldehyde Polymers 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- PXEZTIWVRVSYOK-UHFFFAOYSA-N 2-(3,6-diacetyloxy-2,7-dichloro-9h-xanthen-9-yl)benzoic acid Chemical compound C1=2C=C(Cl)C(OC(=O)C)=CC=2OC2=CC(OC(C)=O)=C(Cl)C=C2C1C1=CC=CC=C1C(O)=O PXEZTIWVRVSYOK-UHFFFAOYSA-N 0.000 description 3
- 230000007730 Akt signaling Effects 0.000 description 3
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 3
- 241001559542 Hippocampus hippocampus Species 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 230000035508 accumulation Effects 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 230000003914 insulin secretion Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000007410 oral glucose tolerance test Methods 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 108010045815 superoxide dismutase 2 Proteins 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 108700013048 CCL2 Proteins 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102100030878 Cytochrome c oxidase subunit 1 Human genes 0.000 description 2
- 101000919849 Homo sapiens Cytochrome c oxidase subunit 1 Proteins 0.000 description 2
- 235000008694 Humulus lupulus Nutrition 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 238000007446 glucose tolerance test Methods 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000006372 lipid accumulation Effects 0.000 description 2
- 210000002311 liver mitochondria Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- MNULEGDCPYONBU-WMBHJXFZSA-N (1r,4s,5e,5'r,6'r,7e,10s,11r,12s,14r,15s,16s,18r,19s,20r,21e,25s,26r,27s,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trio Polymers O([C@@H]1CC[C@@H](/C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)O[C@H]([C@H]2C)[C@H]1C)CC)[C@]12CC[C@@H](C)[C@@H](C[C@H](C)O)O1 MNULEGDCPYONBU-WMBHJXFZSA-N 0.000 description 1
- MNULEGDCPYONBU-DJRUDOHVSA-N (1s,4r,5z,5'r,6'r,7e,10s,11r,12s,14r,15s,18r,19r,20s,21e,26r,27s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers O([C@H]1CC[C@H](\C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)C(C)C(=O)[C@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)OC([C@H]2C)C1C)CC)[C@]12CC[C@@H](C)[C@@H](CC(C)O)O1 MNULEGDCPYONBU-DJRUDOHVSA-N 0.000 description 1
- MNULEGDCPYONBU-YNZHUHFTSA-N (4Z,18Z,20Z)-22-ethyl-7,11,14,15-tetrahydroxy-6'-(2-hydroxypropyl)-5',6,8,10,12,14,16,28,29-nonamethylspiro[2,26-dioxabicyclo[23.3.1]nonacosa-4,18,20-triene-27,2'-oxane]-3,9,13-trione Polymers CC1C(C2C)OC(=O)\C=C/C(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)C\C=C/C=C\C(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-YNZHUHFTSA-N 0.000 description 1
- MNULEGDCPYONBU-VVXVDZGXSA-N (5e,5'r,7e,10s,11r,12s,14s,15r,16r,18r,19s,20r,21e,26r,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers C([C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)OC([C@H]1C)[C@H]2C)\C=C\C=C\C(CC)CCC2OC21CC[C@@H](C)C(C[C@H](C)O)O2 MNULEGDCPYONBU-VVXVDZGXSA-N 0.000 description 1
- MNULEGDCPYONBU-UHFFFAOYSA-N 4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers CC1C(C2C)OC(=O)C=CC(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)CC=CC=CC(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-UHFFFAOYSA-N 0.000 description 1
- UIFFUZWRFRDZJC-UHFFFAOYSA-N Antimycin A1 Natural products CC1OC(=O)C(CCCCCC)C(OC(=O)CC(C)C)C(C)OC(=O)C1NC(=O)C1=CC=CC(NC=O)=C1O UIFFUZWRFRDZJC-UHFFFAOYSA-N 0.000 description 1
- NQWZLRAORXLWDN-UHFFFAOYSA-N Antimycin-A Natural products CCCCCCC(=O)OC1C(C)OC(=O)C(NC(=O)c2ccc(NC=O)cc2O)C(C)OC(=O)C1CCCC NQWZLRAORXLWDN-UHFFFAOYSA-N 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101150052909 CCL2 gene Proteins 0.000 description 1
- 101100504320 Caenorhabditis elegans mcp-1 gene Proteins 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- BMZRVOVNUMQTIN-UHFFFAOYSA-N Carbonyl Cyanide para-Trifluoromethoxyphenylhydrazone Chemical compound FC(F)(F)OC1=CC=C(NN=C(C#N)C#N)C=C1 BMZRVOVNUMQTIN-UHFFFAOYSA-N 0.000 description 1
- 102100027943 Carnitine O-palmitoyltransferase 1, liver isoform Human genes 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 101150080656 DIO2 gene Proteins 0.000 description 1
- 102100024827 Dynamin-1-like protein Human genes 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 102000015782 Electron Transport Complex III Human genes 0.000 description 1
- 108010024882 Electron Transport Complex III Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 101000859570 Homo sapiens Carnitine O-palmitoyltransferase 1, liver isoform Proteins 0.000 description 1
- 101001044612 Homo sapiens Density-regulated protein Proteins 0.000 description 1
- 101000909218 Homo sapiens Dynamin-1-like protein Proteins 0.000 description 1
- 101001018717 Homo sapiens Mitofusin-2 Proteins 0.000 description 1
- 101000973778 Homo sapiens NAD(P)H dehydrogenase [quinone] 1 Proteins 0.000 description 1
- 101000835023 Homo sapiens Transcription factor A, mitochondrial Proteins 0.000 description 1
- 101000841301 Homo sapiens Utrophin Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 102000004034 Kelch-Like ECH-Associated Protein 1 Human genes 0.000 description 1
- 108090000484 Kelch-Like ECH-Associated Protein 1 Proteins 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- 101150046735 LEPR gene Proteins 0.000 description 1
- 101150063827 LEPROT gene Proteins 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 101710091439 Major capsid protein 1 Proteins 0.000 description 1
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 description 1
- 102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 description 1
- 102100033703 Mitofusin-2 Human genes 0.000 description 1
- 101100220687 Mus musculus Cidea gene Proteins 0.000 description 1
- 102100022365 NAD(P)H dehydrogenase [quinone] 1 Human genes 0.000 description 1
- 102000023984 PPAR alpha Human genes 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 108010074436 Sterol Regulatory Element Binding Protein 1 Proteins 0.000 description 1
- 102100026839 Sterol regulatory element-binding protein 1 Human genes 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 1
- 102100038836 Superoxide dismutase [Cu-Zn] Human genes 0.000 description 1
- 102100032891 Superoxide dismutase [Mn], mitochondrial Human genes 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102000008200 Uncoupling Protein 3 Human genes 0.000 description 1
- 108010021098 Uncoupling Protein 3 Proteins 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 238000001790 Welch's t-test Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 210000000593 adipose tissue white Anatomy 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- UIFFUZWRFRDZJC-SBOOETFBSA-N antimycin A Chemical compound C[C@H]1OC(=O)[C@H](CCCCCC)[C@@H](OC(=O)CC(C)C)[C@H](C)OC(=O)[C@H]1NC(=O)C1=CC=CC(NC=O)=C1O UIFFUZWRFRDZJC-SBOOETFBSA-N 0.000 description 1
- PVEVXUMVNWSNIG-UHFFFAOYSA-N antimycin A3 Natural products CC1OC(=O)C(CCCC)C(OC(=O)CC(C)C)C(C)OC(=O)C1NC(=O)C1=CC=CC(NC=O)=C1O PVEVXUMVNWSNIG-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000002989 correction material Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000013118 diabetic mouse model Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000011177 media preparation Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229930191479 oligomycin Natural products 0.000 description 1
- MNULEGDCPYONBU-AWJDAWNUSA-N oligomycin A Polymers O([C@H]1CC[C@H](/C=C/C=C/C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)O[C@@H]([C@@H]2C)[C@@H]1C)CC)[C@@]12CC[C@H](C)[C@H](C[C@@H](C)O)O1 MNULEGDCPYONBU-AWJDAWNUSA-N 0.000 description 1
- 108010007425 oligomycin sensitivity conferring protein Proteins 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013595 supernatant sample Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L17/00—Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
- A23L17/50—Molluscs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B3/00—Hydrogen; Gaseous mixtures containing hydrogen; Separation of hydrogen from mixtures containing it; Purification of hydrogen
- C01B3/0005—Reversible uptake of hydrogen by an appropriate medium, i.e. based on physical or chemical sorption phenomena or on reversible chemical reactions, e.g. for hydrogen storage purposes ; Reversible gettering of hydrogen; Reversible uptake of hydrogen by electrodes
- C01B3/001—Reversible uptake of hydrogen by an appropriate medium, i.e. based on physical or chemical sorption phenomena or on reversible chemical reactions, e.g. for hydrogen storage purposes ; Reversible gettering of hydrogen; Reversible uptake of hydrogen by electrodes characterised by the uptaking medium; Treatment thereof
- C01B3/0015—Organic compounds; Solutions thereof
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B3/00—Hydrogen; Gaseous mixtures containing hydrogen; Separation of hydrogen from mixtures containing it; Purification of hydrogen
- C01B3/02—Production of hydrogen or of gaseous mixtures containing a substantial proportion of hydrogen
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
- Y02E60/30—Hydrogen technology
- Y02E60/36—Hydrogen production from non-carbon containing sources, e.g. by water electrolysis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Combustion & Propulsion (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Botany (AREA)
- Heart & Thoracic Surgery (AREA)
Abstract
本发明公开了储氢牡蛎钙在防治Ⅱ型糖尿病的特殊医学用途食品、保健品及药品中的应用,涉及生物学和医药学技术领域,储氢牡蛎钙在防治Ⅱ型糖尿病的特殊医学用途食品、保健品及药品中的应用,使用储氢牡蛎钙作为固态的载氢剂,能够与水反应产生氢气,可持续释放高浓度氢气,对防治Ⅱ型糖尿病起到显著效果。
Description
技术领域
本发明涉及生物学和医药学技术领域,具体是储氢牡蛎钙在防治Ⅱ型糖尿病的特殊医学用途食品、保健品及药品中的应用。
背景技术
Ⅱ型糖尿病(diabetes mellitus type 2,T2DM)是一种血糖水平升高的慢性代谢疾病,患者表现出高血糖症状,引发高血糖的主要原因是由胰岛素抵抗和胰岛素分泌不足引起。T2DM患者会表现出疲劳、视力模糊、过度口渴、饥饿感及排尿增加。糖尿病发展过程中会引起严重的并发症,包括脂肪肝、肾脏功能衰竭、血脂异常诱发心血管疾病、线粒体功能障碍及氧化损伤导致代谢器官功能异常等疾病发生,累及全身,给人们的生活带来巨大的挑战。2017年世界糖尿病(diabetes mellitus,DM)患病人口约为4.25亿(20~79岁),预计到2045年,糖尿病患病人数将增长至6.29亿。近十年,T2DM全球患病率不断上升,2045年估计中国将有超过1.2亿人患有T2DM。而研究发现,引起T2DM快速增长的原因与快速现代化相关的不健康饮食和生活方式因素(包括久坐行为的增加)密切相关。
现有技术的缺点:目前临床的药物治疗会出现毒副作用,并且会出现严重的肾衰竭,现有的富氢水治疗是一种无副作用的治疗方法,但存在氢气在水中不稳定,不能长时间保存,会很快的逸散掉,不能长时间在体内发挥作用的缺点,因此,无法高效发挥氢气的抗氧化作用。而我们使用储氢牡蛎钙作为固态的载氢剂,能够与水反应产生氢气,可以较长时间维持高浓度氢气的持续释放,可以在生物体内发挥强有力抗氧化治疗作用。
发明内容
本发明的目的在于提供储氢牡蛎钙在防治Ⅱ型糖尿病的特殊医学用途食品、保健品及药品中的应用,以解决上述背景技术中提出的问题。
为实现上述目的,本发明提供如下技术方案:包括使用储氢牡蛎钙作为固态的载氢剂,能够与水反应产生氢气,可持续释放高浓度氢气。
进一步地,其储氢牡蛎钙治疗可以显著的降低附睾脂肪和肾周脂肪重量。
进一步地,其储氢牡蛎钙显著的降低空腹血糖水平和改善葡萄糖耐受。
进一步地,其储氢牡蛎钙治疗可以显著的降低血清中FFA、TG和TC的水平。
进一步地,其储氢牡蛎钙治疗可以显著的降低肝脏组织中TG和TC的水平及抑制肝脏和肌肉组织中脂质的合成,并促进棕色脂肪组织脂质代谢。
进一步地,其储氢牡蛎钙治疗可以显著的降低肾脏组织中炎性因子的表达水平。
与现有技术相比,本发明的有益效果是:
1.储氢牡蛎钙治疗可以显著的降低附睾脂肪和肾周脂肪重量,在储氢牡蛎钙治疗Ⅱ型糖尿病导致肥胖或者其他因素导致肥胖中的减肥应用。
2.储氢牡蛎钙治疗治疗可以显著的降低空腹血糖水平和改善葡萄糖耐受,在储氢牡蛎钙治疗Ⅱ型糖尿病或葡萄糖耐受疾病的应用。
3.储氢牡蛎钙治疗降低血清中FFA、TG和TC的水平,在治疗预防心血管、高血脂和脂肪肝等疾病的应用。
4.储氢牡蛎钙治疗可以显著的降低肝脏组织中TG和TC的水平及抑制肝脏和肌肉组织中脂质的合成,并促进棕色脂肪组织脂质代谢,在防治Ⅱ型糖尿病导致的脂肪肝及其它因素导致的脂肪肝方面应用。
5.储氢牡蛎钙治疗可以显著的降低肾脏组织中炎性因子的表达水平,在防治T2DM引发的肾病及其它肾脏炎症疾病的应用。
附图说明
图1为储氢牡蛎钙(HOP)体外持续释放氢气情况;
图2为储氢牡蛎钙(HOP)治疗对db/db小鼠过程中,可减轻肾周脂肪和附睾脂肪重量;
图3为储氢牡蛎钙(HOP)治疗促进db/db小鼠胰岛素的分泌及激活肌肉AKT信号通路,改善小鼠葡萄糖耐受;
图4为储氢牡蛎钙(HOP)治疗db/db小鼠,降低血清中TG(甘油三脂)、TC(胆固醇)及FFA(游离脂肪酸)水平;
图5为储氢牡蛎钙(HOP)治疗db/db小鼠,降低肝脏组织血清中TG(甘油三脂)、TC(胆固醇)积累及抑制肝脏和肌肉组织脂质合成,并促进棕色脂肪组织脂质代谢;
图6为储氢牡蛎钙(HOP)治疗db/db小鼠,降低脑、肌肉和心脏组织的活性氧(ROS)及氧化应激;
图7为储氢牡蛎钙(HOP)治疗db/db小鼠改善肝脏和脑组织线粒体功能;
图8为储氢牡蛎钙(HOP)治疗降低了db/db小鼠肾脏组织中炎性因子水平。
具体实施方式
下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行清楚、完整地描述,实施例中采用的lepr db突变小鼠(db/db)是常见的糖尿病小鼠模型。显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
为了阐明HOP在体内对T2DM的治疗效果,设计的实验方案为:给db糖尿病小鼠灌胃HOP,通过检测血糖,血脂,肝脏组织中脂质的累积及关键代谢组织的脂代谢,关键代谢组织中活性氧水平及抗氧化蛋白来评价HOP在治疗T2DM中的应用。
请参阅图1~8,本发明实施例中,HOP体外释放氢气的检测方法:准确称取不同剂量的储氢牡蛎钙粉末,用水分别配制浓度为30mg/mL,100mg/mL,300mg/mL的储氢牡蛎钙水溶液5mL置于20mL的小烧饼中,轻轻搅拌混合均匀后,密封烧杯口,待检测时打开烧杯,用氢电极检测水溶液中氢气的浓度。分别检测1h,4h,8h,24h,48h,72h,96h,120h,144h,168h,192h储氢牡蛎钙释放氢气的浓度,同时测定溶液的PH。
动物模型:
(1)Ⅱ型糖尿病模型:
购买选择4-5周龄大小的db小鼠12只,在适应环境后,将小鼠随机分为2组:
A.db 8
B.db+储氢牡蛎钙(HOP,300mg/kg,预防组) 4
在小鼠适应环境后,分别给予实验组小鼠(B组)300mg/kg的储氢牡蛎钙,A组给予等剂量的生理盐水。
(2)动物实验方案分组:
在db小鼠的血糖显著升高后,将上述A组db小鼠进行随机分组2组,然后给分别给予C组储氢牡蛎钙(HOP)对糖尿病小鼠进行治疗干预:
A.db/db 5
B.db/db+HOP-P(300mg/kg,预防组) 4
C.db/db+HOP-T(300mg/kg,治疗组) 3
动物适应环境后,然后灌胃储氢牡蛎钙,老鼠体重和进食量每周记录2次,实验持续时间为4个月,随机血糖,空腹血糖,出现明显效果后,小鼠禁食过夜后,处死小鼠,收集各种代谢组织(脑,心脏,肝脏,肌肉,脂肪(棕色脂肪,附睾脂肪和肾周脂肪),肾脏),胰腺,血清。其中固定肝脏,白色脂肪(若观察到明显区别),肾脏固定。
实验方法
1).活性氧(ROS)水平测定
(1)H2DCF-DA储存液配制:H2DCF-DA试剂配制成10mmol/L的储存液,如表1,配置过程中需注意避光,配制好的储备液分装成小份,置于-20℃避光保存。
(2)组织中活性氧的测定:称取20mg组织,用剪刀剪碎,然后使用预定的PBS清洗一遍,重新加入200μL的预冷PBS,使用组织研磨器进行研磨,研磨匀浆后,4℃,1000g离心10min,取上清,然后重复离心一次,收取上清到心的1.5mL离心管,取10μL加入到96孔板,然后将H2DCF-DA试剂用PBS稀释1000倍,每孔加入100μL,将96孔板避光37℃孵育30min,放入酶标仪进行荧光检测,设定激发光和发射光为485nm和538nm;同时将测定上清样品进行BCA蛋白定量;组织中ROS含量为荧光OD值与相应蛋白含量的比值。
2).蛋白质印记
从细胞裂解液中提取总蛋白,在SDS-PAGE胶进行蛋白质分离,并印染至PVDF薄膜上。1%牛血清白蛋白封闭1小时后,用特定的一抗在4oC孵育过夜。第二天,用辣根过氧化物酶交联的二抗室温孵育1小时后,将条带在加强的化学发光仪上进行显影(Bio-RadLaboratories,Hercules,CA,USA)。
Anti-TFAM(D5C8,#8076s)抗体,Anti-β-Actin(8H10D10,#3700S)抗体和Anti-GAPDH(14C10,#2118S)抗体,PPARγ(2435S)抗体,FAS(3189S)抗体,α-Tubulin(3873S)抗体,Anti-P-ACC(#3661s)抗体,Anti-ACC(3676S)抗体购自Cell Signaling Technology(Danvers,MA)。Anti-NDUFS3(ComplexⅠ,#459130)抗体,Anti-SDHB(ComplexⅡ,#459230)抗体,Anti-UQCRC1(ComplexⅢ,#45914)抗体,Anti-MTCO1(ComplexⅣ,#459600)抗体,Anti-ATP Synthase Subunit Alpha(ComplexⅤ,#459240)抗体购自Invitrogen(Meridian,USA)。Anti-DRP1(
611113)抗体和Anti-OPA1(612607)抗体购自BD Biosciences(Mexico,US)。Anti-MFN1(D-10,sc-166644)抗体,Anti-MFN2(F-5,sc-515647)抗体,Anti-NQO1(H-9,Sc-376023)抗体,Anti-SOD1(24,Sc-101523)抗体,Anti-SOD2(E-10,Sc-137254)抗体和Anti-catalase(F-17,Sc-34285)抗体,PPARα(sc-9000)抗体,SREBP1(Sc13551)抗体购自SantaCruz Biotechnology(Dallas,TX)。Anti-KEAP1(#60027-1-Ig)抗体和Anti-NRF2(#66504-1-Ig)抗体购自Proteintech(Rosemont,IL)。CPT1A(A5307)抗体,UCP1(A5857)抗体,UCP3(A16996)抗体购自ABclonal(Wuhan,China)。
3).实时定量PCR
使用TriPure Isolation Reagent(Roche,Basel,Switzerland)从细胞中提取总RNA,然后利用试剂盒(BioRad,Hercules,CA,USA)反转录成cDNA。使用iQ SYBR GreenSupermix(BioRad)进行PCR反应,并利用CFX Connect real-time PCR detection system(BioRad)进行数据分析。目标基因的引物经设计、合成后,用灭菌超纯水溶解成100μM的储备液,-20℃保存。临用前将上、下游引物混合,稀释10倍后得终浓度为10μM的应用液。TG和TC水平的测定
根据购买的南京建成公司的检测试剂盒中的操作说明书,检测血清中和肝脏组织中TG和TC水平,具体操作步骤按照说明书进行操作。
4)口服糖耐量实验(OGTT)
小鼠葡萄糖耐受量(Glucose tolerance tests,GTT)检测。小鼠禁食过夜(12小时)之后尾静脉取血并测量小鼠的血糖水平,按照1.5g/kg的剂量腹腔注射葡萄糖溶液。在葡萄糖给药前后,在规定时间点(0、15、30、60和120min)从尾静脉抽取血样,血糖仪测量血糖水平并记录实验数据。
5)胰岛素敏感性实验(ITT)
小鼠胰岛素耐受量(Insulin tolerance test,ITT)检测,小鼠禁食6小时之后,测量小鼠血糖记录为0点,腹腔注射胰岛素(0.75U/kg)。在胰岛素给药之后15、30、60和120min从尾静脉抽取血样,使用血糖仪测量血糖水平并记录实验数据。
6)组织HE切片染色
首先将组织样本使用4%的多聚甲醛固定,然后石蜡包埋。包埋完成后切片厚度在4-8μm左右;样本脱蜡和水化;切片苏木素染色、分化与反蓝;切片伊红染色与脱水;HE染色样本切片风干封片;最后在显微镜下观察并拍照
7)油红染色
取适量肝脏组织,4%的多聚甲醛固定24h以上,然后冰冻切片10μm薄片,染色前蒸馏水充分洗剂;油红稀释液染色10-15分钟,避光密封;然后进行水洗,marry氏苏木素复染核,最后水洗封片,在显微镜下拍照保存。
8)线粒体提取
(1)线粒体分离介质配制:配制500mL线粒体分离介质:称取0.6g Tris base,42.79g蔗糖,0.19g EDTA二钠盐,充分溶解,调节PH至7.4。
(2)剪取黄豆粒大小的小鼠组织于1.5mL的EP管中,加PBS清洗,将残留的血液去除干净,加入一定量的含1%PSMF的线粒体分离介质,用剪刀将组织块尽量剪碎;然后使用玻璃匀浆器上下研磨60次,使细胞破碎释放线粒体;
(3)匀浆于4℃,150g,离心10min,取上清重复离心2-3次;
(4)上清于4℃,1000g离心10min,取上清重复离心2次;
(5)上清于4℃,10000g离心15min,取上清重复离心2-3次,沉淀即为线粒体;
(6)用线粒体分离介质重悬清洗线粒体沉淀3次,4℃,10000g离心15min,加入适量的含1%PSMF线粒体分离介质重悬沉淀,即为线粒体,备用;
9)线粒体功能的检测
(1)活化Seahorse探针,待探针活化好后,取细胞培养板,每孔加入3μg线粒体,然后加入线粒体呼吸液;
(2)放置在37℃无CO2培养箱中静置8-10min,待探针校正后放入机器检测;
(3)探针孔分别加入4mM ADP,1μM Oligomycin,1μM FCCP,2μM Antimycin A代谢底物和抑制剂;
(4)将含有校正液的探针放入仪器中,按程序设置进行校正,待校正完成后上机检测;
10)统计分析
使用Graphpad Prism8软件进行统计分析。首先采用Shapiro-Wilk正态性检验检验样本的正态分布。如果符合正态分布,则进一步检验方差齐性。如果数据也通过了方差齐性检验,则使用双尾Student t-text或One-way ANOVA(Tukey事后检验)计算p值;否则,使用Welch t检验或Kruskal-Wallis检验计算p值。对于不符合正态分布的样本,使用Mann-Whitney或Kruskal-Wallis非参数检验。数据以平均值±SEM表示。显著统计学意义为*p<0.05,**p<0.01,***p<0.001。
图1为HOP体外持续释放氢气情况。A为浓度为30mg/mL,100mg/mL,300mg/mL的储氢牡蛎钙水溶液在192h内持续释放氢气浓度的情况。B为浓度为30mg/mL,100mg/mL,300mg/mL的储氢牡蛎钙水溶液在192h内随氢气释放,溶液的PH监测情况(n=3,***p<0.001)。
图2为HOP治疗对db/db小鼠过程中,可减轻肾周脂肪和附睾脂肪重量。A为HOP治疗过程中,对小鼠体重的监测。B为HOP治疗结束后,对小鼠体重增量的监测。C为HOP治疗过程中,对小鼠摄食量的监测。D为HOP治疗过程中,对小鼠饮水量的监测。E为HOP治疗结束后,对小鼠的肾周脂肪称重。D为为HOP治疗结束后,对小鼠的附睾脂肪称重(db/db,n=5;db+HOP-P,n=4;db/db+HOP-T,n=3;*p<0.05)。
图3为HOP治疗促进db/db小鼠胰岛素的分泌及激活肌肉AKT信号通路,改善小鼠葡萄糖耐受。图A为HOP预防8周,治疗2周,使用罗氏血糖仪通过尾静脉采血监测小鼠的空腹血糖结果。图B为HOP预防10周,治疗4周,使用罗氏血糖仪通过尾静脉采血监测小鼠的空腹血糖结果。图C为HOP预防11周,治疗5周,使用罗氏血糖仪通过尾静脉采血监测小鼠葡萄糖耐量结果。图D为HOP预防18周,治疗10周,使用elisa试剂盒检测小鼠血清中胰岛素结果。图E为HOP治疗后,通过提取组织全蛋白使用Western blot分析P-AKT和AKT蛋白水平,使用elisa试剂盒检测小鼠血清中胰岛素结果(db/db,n=5;db+HOP-P,n=4;db/db+HOP-T,n=3;*p<0.05,**p<0.01;***p<0.001)。
图4为HOP治疗db/db小鼠,降低血清中TG(甘油三脂)、TC(胆固醇)及FFA(游离脂肪酸)水平。图A为HOP预防8周,治疗2周,使用碧云天商品化TG和TC试剂盒检测血清中TG和TC结果。图B为HOP预防13周,治疗7周,使用碧云天商品化TG和TC试剂盒检测血清中TG和TC结果。图C为HOP预防18周,治疗10周,使用碧云天商品化TG和TC试剂盒检测血清中TG和TC结果。图D为HOP预防18周,治疗10周,使用elisa试剂盒检测小鼠血清中FFA结果。(db/db,n=5;db+HOP-P,n=4;db/db+HOP-T,n=3;*p<0.05,**p<0.01;***p<0.001)。
图5为HOP治疗db/db小鼠,降低肝脏组织血清中TG(甘油三脂)、TC(胆固醇)积累及抑制肝脏和肌肉组织脂质合成,并促进棕色脂肪组织脂质代谢。图A为HOP治疗后,使用碧云天商品化TG和TC试剂盒检测肝脏组织中TG和TC结果。图B为HOP治疗后,用4%的多聚甲醛固定肝脏组织,进行切片HE染色结果。图C为HOP治疗后,用4%的多聚甲醛固定肝脏组织,进行切片油红染色结果。图D为HOP治疗后,裂解肝脏组织蛋白,通过Western blot分析脂质合成和脂质分析相关蛋白的表达水平。图E为HOP治疗后,裂解肌肉组织蛋白,通过Western blot分析脂质合成和脂质分析相关蛋白的表达水平。图F为HOP治疗后,提取棕色脂肪组织(BAT)RNA,通过qRT-PCR分析脂质合成和脂质分析相关基因的表达水平。(db/db,n=5;db+HOP-P,n=4;db/db+HOP-T,n=3;*p<0.05,**p<0.01;***p<0.001)。
图6为HOP治疗db/db小鼠,降低脑、肌肉和心脏组织的活性氧(ROS)及氧化应激。图A为HOP治疗后,通过H2DCFDA(一种标记ROS的染料)荧光染色标记脑组织活性氧水平。图B为HOP治疗后,通过H2DCFDA(一种标记ROS的染料)荧光染色标记肌肉组织活性氧水平。图C为HOP治疗后,通过H2DCFDA(一种标记ROS的染料)荧光染色标记心脏组织活性氧水平。图D为HOP治疗后,裂解脑组织蛋白,通过Western blot分析抗氧化相关蛋白的表达水平。图E为HOP治疗后,裂解肌肉组织蛋白,通过Western blot分析抗氧化相关蛋白的表达水平。图为HOP治疗后,裂解心脏组织蛋白,通过Western blot分析抗氧化相关蛋白的表达水平。(db/db,n=5;db+HOP-P,n=4;db/db+HOP-T,n=3;*p<0.05,**p<0.01)。
图7为HOP治疗db/db小鼠改善肝脏和脑组织线粒体功能。图A为提取肝脏线粒体,通过seahorse检测肝脏组织氧气消化速率。图B为HOP治疗后,裂解肝脏组织蛋白,通过Western blot分析线粒体相关蛋白的表达水平。图C为HOP治疗后,裂解脑组织蛋白,通过Western blot分析线粒体相关蛋白的表达水平。图为HOP治疗后,裂解心脏组织蛋白,通过Western blot分析抗氧化相关蛋白的表达水平。(db/db,n=5;db+HOP-P,n=4;db/db+HOP-T,n=3;*p<0.05,**p<0.01)。
图8HOP治疗降低了db/db小鼠肾脏组织中炎性因子水平。图为HOP治疗后,提取肾脏组织RNA,通过qRT-PCR分析炎性因子TNFα和MCP1表达水平。(db/db,n=5;db+HOP-P,n=4;db/db+HOP-T,n=3;*p<0.05,***p<0.001)。
下面给出本发明实验的相关结果。
(一)HOP体外持续释放高效氢气。
为了明确储氢牡蛎钙在体外释放氢气的情况,首先准确称取不同剂量的储氢牡蛎钙粉末(HOP),用水分别配制浓度为30mg/mL,100mg/mL,300mg/mL的储氢牡蛎钙水溶液5mL置于20mL的小烧饼中,轻轻搅拌混合均匀后,密封烧杯口,待检测时打开烧杯,用氢电极检测水溶液中氢气的浓度。分别检测1h,4h,8h,24h,48h,72h,96h,120h,144h,168h,192h储氢牡蛎钙释放氢气的浓度,同时测定溶液的PH,检测结果如图1所示,图1(A)中我们发现30mg/mL,100mg/mL,300mg/mL的储氢牡蛎钙水溶液中氢气的浓度随着时间的增加先升高后降低,并且,30mg/mL,100mg/mL,300mg/mL的储氢牡蛎钙水溶液在8h氢气的浓度达到巅峰(氢气的峰值浓度分别为520ppb,600ppb,740ppb),随着储氢牡蛎钙浓度的增加,释放氢气的浓度也是增加的,300mg/ml储氢牡蛎钙水溶液释放氢气的浓度显著高于30mg/mL和100mg/mL,随着时间的延长,氢气的释放逐渐下降,30mg/mL储氢牡蛎钙水溶液在96h后氢气释放为0,100mg/mL的储氢牡蛎钙水溶液在120h后氢气释放为0,300mg/mL的储氢牡蛎钙水溶液在192h后氢气释放为0;PH检测检测结果如图1(B)所示,储氢牡蛎钙水溶液均呈现碱性(PH>8),且随着浓度的升高,储氢牡蛎钙水溶液的PH呈现显著性的升高,高剂量300mg/mL的储氢牡蛎钙水溶液PH大于13可以维持96h,然后开始降低,100mg/mL的储氢牡蛎钙水溶液PH大于12维持24h,之后开始逐渐降低,30mg/mL储氢牡蛎钙水溶液PH大于12维持8h,然后开始逐渐降低。
(二)HOP治疗可以降低db/db小鼠肾周脂肪和附睾脂肪重量。
为了明确储氢牡蛎钙在体内的作用效果,我们选择db/db小鼠作为研究对象,给db/db小鼠灌胃300mg/kg的HOP,在持续治疗过程中检测体重,摄食量和饮水量,最终治疗结束后,取材进行分析。图2A-D结果表明,预防组(HOP)和治疗组(HOP-T)对小鼠的体重、摄食量、饮水量及体重增量没有影响,HOP预防组可以显著的降低db/db小鼠的肾周脂肪和附睾脂肪的重量(图2E-F)。这表明HOP治疗对Ⅱ型糖尿病具有潜在的减脂效果。
(三)HOP治疗提升db/db小鼠胰岛素的分泌及激活AKT信号通路,改善小鼠葡萄糖耐受。
为了探究HOP治疗对db小鼠血糖的改善作用,我们采用尾静脉采血,用罗氏活力血糖试纸检测db小鼠的空腹血糖和葡萄糖耐量的改善作用。在HOP预防组(HOP-P)治疗8周和HOP治疗组(HOP-T)治疗2周时,可以显著的降低db/db小鼠的空腹血糖(图3A)。继续监测,发现HOP治疗组(HOP-T)治疗4周时,可以显著的降低db/db小鼠的空腹血糖(图3B)。在HOP预防组(HOP-P)治疗11周和HOP治疗组(HOP-T)治疗5周时,我们检测一次口服葡萄糖耐量(OGTT)检测,发现HOP-P和HOP-T治疗组空腹血糖显著降低,且HOP-P和HOP-T治疗组小鼠口服葡萄糖耐量(OGTT)曲线下积分面积显著降低,这表明HOP的预防和治疗均可以显著的改善db/db小鼠的葡萄糖耐受(图3C)。进一步研究发现,HOP-T治疗12周后可以显著的增加血清中insulin的水平(图3D),这也是HOP改善血糖的重要原因之一。同时,还发现HOP预防组可以显著的提高小鼠肌肉组织中P-AKT的水平(图3E)。以上结果表明HOP对db/db小鼠的预防和治疗均可以显著改善空腹血糖和葡萄糖耐受。
(四)HOP治疗可以显著的降低db/db小鼠血脂水平。
为了探究HOP治疗对db/db小鼠血脂的改善作用,我们采用尾静脉采血,然后使用商品化甘油三脂(TG)和胆固醇(TC)检测试剂盒检测血清中甘油三脂和胆固醇的水平。在HOP预防组(HOP-P)治疗8周和HOP治疗组(HOP-T)治疗2周时,可以显著的降低db/db小鼠的空腹TG和TC的水平(图4A)。继续监测,发现在HOP预防组(HOP-P)治疗13周和HOP治疗组(HOP-T)治疗7周时,可以显著的降低db/db小鼠的血清中TG和TC的水平(图4B)。在HOP预防组(HOP-P)治疗18周,发现HOP-P治疗组血清中TG水平显著降低(图4C)。在HOP预防组(HOP-P)治疗18周和HOP治疗组(HOP-T)治疗12周,发现HOP-P治疗组血清中自由脂肪酸(Freefatty acid,FFA)水平显著降低(图4D)。以上结果表明HOP对db/db小鼠的预防和治疗均可以显著降低血脂的水平。
(五)HOP治疗可以降低db/db小鼠肝脏组织中脂质的积累及抑制肝脏和肌肉中脂质合成,促进棕色脂肪的脂肪酸代谢。
为了探究HOP治疗对db/db小鼠脂肪肝改善作用,然后使用商品化甘油三脂(TG)和胆固醇(TC)检测试剂盒检测肝脏组织中甘油三脂和胆固醇的水平。发现HOP预防组(HOP-P)治疗可以显著的降低db/db小鼠肝脏组织中TG和TC的水平(图5A)。同时,肝脏组织的HE染色和油红染色表明,HOP预防和治疗均可以降低肝脏组织脂质的积累,特别是HOP预防组的效果非常显著(图5B,C)。进一步深入研究发现,HOP治疗组可以显著的降低肝脏组织中P-ACC和肌肉组织ACC的蛋白水平,这表明HOP可以抑制肝脏和肌肉组织中脂质的合成(图5D,E)。此外,棕色脂肪中,HOP治疗组可以显著的升高Ucp1,Pparα,Pparγ,Cidea,Prdm16及Dio2等脂代谢相关基因的表达水平,HOP预防组可以显著的升高Pparα,Pparγ及Prdm16的基因表达水平,还发现HOP治疗组可以显著的增加线粒体生成相关转录因子Pgc1α的水平(图5F)。以上结果表明HOP预防治疗可以降低db/db小鼠肝脏组织中TG和TC的水平,这与HOP可以抑制肝脏组织和肌肉组织的脂质合成及促进棕色脂肪脂质代谢密切相关,HOP的治疗可为改善db/db小鼠的脂肪肝提供理论支持。
(六)HOP治疗降低了db/db小鼠脑、肌肉和心脏的组织的氧化应激。
为了探究HOP治疗对db/db小鼠关键代谢组织氧化应激的作用,我们检测了脑,肌肉和心脏等组织中活性氧的水平及抗氧化相关KEAP1-NRF2信号通路蛋白的表达水平变化。在脑组织中,与对照组db/db小鼠相比,发现HOP-T和HOP-P治疗可以显著降低脑组织中ROS水平,且抗氧化相关蛋白KEAP1、NQO1、Catalase及SOD2蛋白水平显著升高(图6A,D);在肌肉组织中,与对照组db/db小鼠相比,发现HOP-P和HOP-T治疗可以显著降低肌肉组织中ROS水平,尽管抗氧化蛋白Catalase、SOD2及SOD1的表达是下降的,这可能与HOP的治疗显著降低ROS水平,从而降低肌肉组织的氧化应激密切相关(图6B,E);在心脏组织中,与对照组db/db小鼠相比,发现HOP-T治疗可以显著降低心脏组织中ROS水平,且提高了SOD2蛋白的表达(图6C,F)。以上的研究结果显示,HOP的治疗可以显著的改善肌肉,心脏,脑组织中活性氧的水平,降低这些代谢组织的氧化压力,这对于保护关键代谢组织的氧化损伤具有重要的意义。
(七)HOP治疗改善肝脏和脑组织线粒体的功能。
为了进一步探究HOP治疗对肝脏和脑组织线粒体的影响,首先提取了肝脏组织的线粒体,通过Seahorse评价肝脏线粒体呼吸功能及通过WB评价肝脏组织和脑组织线粒体相关蛋白的表达水平,结果发现,HOP预防组(HOP-P)治疗可以显著的提高肝脏线粒体的最大呼吸能力,同时HOP的治疗提高线粒体蛋白TFAM、MTCO1及DRP1蛋白表达水平(图7A,B)。此外,还发现HOP-T治疗显著的提高脑组织MFN2及MTCO1蛋白表达水平(图7C)。这些结果表明,HOP的治疗可以显著改善肝脏和脑组织线粒体的功能。
(八)HOP治疗降低db/db小鼠肾脏组织中炎性因子的水平。
为了探究HOP治疗对db小鼠炎症的作用,我们检测了肾脏组织中炎性因子转录水平。在肾脏组织中,与对照组db小鼠相比,发现HOP-P治疗可以显著降低肾脏组织中肿瘤坏死因子(tumor necrosis factor,Tnfα)和趋化因子(C-C基序)配体2(chemokine(C-Cmotif)ligand 2,Mcp1)炎性因子水平(图8);HOP-T可以显著的降低肾脏组织中Mcp1的水平,这些结果显示,HOP治疗db小鼠可以显著的改善肾脏组织的炎症。
对于本领域技术人员而言,显然本发明不限于上述示范性实施例的细节,而且在不背离本发明的精神或基本特征的情况下,能够以其他的具体形式实现本发明。因此,无论从哪一点来看,均应将实施例看作是示范性的,而且是非限制性的,本发明的范围由所附权利要求而不是上述说明限定,因此旨在将落在权利要求的等同要件的含义和范围内的所有变化囊括在本发明内,不应将权利要求中的任何附图标记视为限制所涉及的权利要求。
此外,应当理解,虽然本说明书按照实施方式加以描述,但并非每个实施方式仅包含一个独立的技术方案,说明书的这种叙述方式仅仅是为清楚起见,本领域技术人员应当将说明书作为一个整体,各实施例中的技术方案也可以经适当组合,形成本领域技术人员可以理解的其他实施方式。
Claims (6)
1.储氢牡蛎钙在防治Ⅱ型糖尿病的特殊医学用途食品、保健品及药品中的应用,其特征在于,使用储氢牡蛎钙作为固态的载氢剂,能够与水反应产生氢气,可持续释放高浓度氢气。
2.根据权利要求1的应用,其特征在于,其储氢牡蛎钙治疗可以显著的降低附睾脂肪和肾周脂肪重量。
3.根据权利要求1的应用,其特征在于,其储氢牡蛎钙显著的降低空腹血糖水平和改善葡萄糖耐受。
4.根据权利要求1的应用,其特征在于,其储氢牡蛎钙治疗可以显著的降低血清中FFA、TG和TC的水平。
5.根据权利要求1的应用,其特征在于,其储氢牡蛎钙治疗可以显著的降低肝脏组织中TG和TC的水平及抑制肝脏和肌肉组织中脂质的合成,并促进棕色脂肪组织脂质代谢。
6.根据权利要求1的应用,其特征在于,其储氢牡蛎钙治疗可以显著的降低肾脏组织中炎性因子的表达水平。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310662633.8A CN116671631A (zh) | 2023-06-06 | 2023-06-06 | 储氢牡蛎钙在防治ⅱ型糖尿病的特殊医学用途食品、保健品及药品中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310662633.8A CN116671631A (zh) | 2023-06-06 | 2023-06-06 | 储氢牡蛎钙在防治ⅱ型糖尿病的特殊医学用途食品、保健品及药品中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116671631A true CN116671631A (zh) | 2023-09-01 |
Family
ID=87778660
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310662633.8A Pending CN116671631A (zh) | 2023-06-06 | 2023-06-06 | 储氢牡蛎钙在防治ⅱ型糖尿病的特殊医学用途食品、保健品及药品中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116671631A (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102524785A (zh) * | 2012-02-08 | 2012-07-04 | 姚鼎山 | 一种负氢离子粉体及其制备方法 |
CN103710028A (zh) * | 2013-12-31 | 2014-04-09 | 王绪珍 | 担载负氢离子的粉体及其制备方法 |
CN115708838A (zh) * | 2022-11-14 | 2023-02-24 | 日照生命谷生物科技发展股份公司 | 一种牡蛎负氢片及其制备方法 |
-
2023
- 2023-06-06 CN CN202310662633.8A patent/CN116671631A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102524785A (zh) * | 2012-02-08 | 2012-07-04 | 姚鼎山 | 一种负氢离子粉体及其制备方法 |
CN103710028A (zh) * | 2013-12-31 | 2014-04-09 | 王绪珍 | 担载负氢离子的粉体及其制备方法 |
CN115708838A (zh) * | 2022-11-14 | 2023-02-24 | 日照生命谷生物科技发展股份公司 | 一种牡蛎负氢片及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ma et al. | Bakuchiol alleviates hyperglycemia-induced diabetic cardiomyopathy by reducing myocardial oxidative stress via activating the SIRT1/Nrf2 signaling pathway | |
Wang et al. | Icariin prevents extracellular matrix accumulation and ameliorates experimental diabetic kidney disease by inhibiting oxidative stress via GPER mediated p62-dependent Keap1 degradation and Nrf2 activation | |
Ge et al. | Endoplasmic reticulum stress-induced iRhom2 up-regulation promotes macrophage-regulated cardiac inflammation and lipid deposition in high fat diet (HFD)-challenged mice: Intervention of fisetin and metformin | |
US20070088078A1 (en) | Methods for managing adipocyte fat accumulation | |
Ge et al. | Fisetin supplementation prevents high fat diet-induced diabetic nephropathy by repressing insulin resistance and RIP3-regulated inflammation | |
Ren et al. | Protection of hepatocyte mitochondrial function by blueberry juice and probiotics via SIRT1 regulation in non-alcoholic fatty liver disease | |
Jang et al. | The effect of dietary α-lipoic acid, betaine, l-carnitine, and swimming on the obesity of mice induced by a high-fat diet | |
Drzewoski et al. | The role of “metabolic memory” in the natural history of diabetes mellitus | |
WO2011022944A1 (zh) | 以羊毛甾烷及茯苓萃取物治疗糖尿病的用途 | |
CN111407879B (zh) | 山药蛋白提取物在制备治疗勃起功能障碍的药物中的应用 | |
Hua et al. | Metformin increases cardiac rupture after myocardial infarction via the AMPK-MTOR/PGC-1α signaling pathway in rats with acute myocardial infarction | |
Wang et al. | Melatonin attenuates diabetic myocardial microvascular injury through activating the AMPK/SIRT1 signaling pathway | |
Yuvanc et al. | Investigation of the antioxidant effects of pheniramine maleate and nebivolol on testicular damage in rats with experimentally induced testis torsion | |
WO2019091397A1 (zh) | 叠氮根皮苷素在制备治疗非酒精性脂肪肝药物中的用途 | |
CN116671631A (zh) | 储氢牡蛎钙在防治ⅱ型糖尿病的特殊医学用途食品、保健品及药品中的应用 | |
Apaijit et al. | Hesperidin alleviates vascular dysfunction and remodelling in high-fat/high-fructose diet-fed rats by modulating oxidative stress, inflammation, AdipoR1, and eNOS expression | |
CN106963803B (zh) | 绞股蓝总黄酮在制备防治心肌肥厚的药物中的应用 | |
Deng et al. | Syringin alleviates hepatic fibrosis by enhancing autophagic flux and attenuating ER stress-TRIB3/SMAD3 in diabetic mice | |
Jeje et al. | Effects of maternal dexamethasone exposure during lactation on metabolic imbalance and oxidative stress in the liver of male offsprings of Wistar rats | |
Jarad et al. | Effect of L-arginine on spermatogenesis of the diabetic rat | |
Yokozawa et al. | Attenuating effects of Wen-Pi-Tang treatment in rats with diabetic nephropathy | |
CN116671630A (zh) | 储氢牡蛎钙在防治肥胖、胰岛素抵抗和脂肪肝的特殊医学用途食品、保健品及药品中的应用 | |
Eldamarawi et al. | Effect of quercetin and metformin on glucose transporter-4 expression, oxidative stress, inflammation markers and insulin resistance in type 2 diabetes mellitus | |
CN116671633A (zh) | 储氢牡蛎钙在防治ⅰ型糖尿病的特殊医学用途食品、保健品及药品中的应用 | |
CN110613851A (zh) | 二至方在制备防治良性前列腺增生症的药物中的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |